Francis Burrows
Biogen Idec
CancerCyclin-dependent kinaseInternal medicinePathologyMolecular biologyKinaseChemistryApoptosisHeat shock proteinIn vivoHsp90TipifarnibHsp90 inhibitorCell cycleCancer researchBiochemistrySignal transductionMedicineCell cultureBiologyPharmacology
Publications 103
#1Rong Chen (University of Texas MD Anderson Cancer Center)H-Index: 14
#2Jennifer W. Tsai (Yale University)H-Index: 1
Last. William Plunkett (University of Texas MD Anderson Cancer Center)H-Index: 101
view all 12 authors...
The constitutive activation of B-cell receptor (BCR) signaling, together with the overexpression of the Bcl-2 family anti-apoptotic proteins, represents two hallmarks of chronic lymphocytic leukemia (CLL) that drive leukemia cell proliferation and sustain their survival. TG02 is a small molecule multi-kinase inhibitor that simultaneously targets both of these facets of CLL pathogenesis. First, its inhibition of cyclin-dependent kinase 9 blocked the activation of RNA polymerase II and transcripti...
#1Eunice S. WangH-Index: 35
#2Jessica K. Altman (NU: Northwestern University)H-Index: 53
Last. Amir T. Fathi (Harvard University)H-Index: 46
view all 10 authors...
3 CitationsSource
#1Francis BurrowsH-Index: 29
#2M. ShivaniH-Index: 1
Last. S. GutkindH-Index: 1
view all 6 authors...
1 CitationsSource
#1Mara Gilardi (UCSD: University of California, San Diego)H-Index: 11
#2Zhiyong Wang (UCSD: University of California, San Diego)H-Index: 51
Last. Francis BurrowsH-Index: 29
view all 14 authors...
Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational attachment of farnesyl groups to signaling proteins that are required for localization to cell membranes. Although all RAS isoforms are FT substrates, only HRAS is exclusively dependent upon farnesylation, raising the possibility that HRAS mutant tumors might be susceptible to tipifarnib-mediated inhibition of FT. Here, we report the characterization of tipifarnib activity in a ...
8 CitationsSource
#1Francis BurrowsH-Index: 29
Last. J. Silvio Gutkind (UCSD: University of California, San Diego)H-Index: 119
view all 5 authors...
e15658Background: HRAS is an important driver oncogene in HNSCC and other squamous cell carcinomas (SCCs). HRAS mutations are observed in 6-10% of HNSCC cases and appear to define a unique subset o...
#1Szymon Klossowski (UM: University of Michigan)H-Index: 12
#2Hongzhi Miao (UM: University of Michigan)H-Index: 18
Last. Jolanta GrembeckaH-Index: 23
view all 35 authors...
The protein-protein interaction between menin and mixed lineage leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the nucleophosmin 1 (NPM1) gene. As a step toward clinical translation of menin-MLL1 inhibitors, we report development of MI-3454, a highly potent and orally bioavailable inhibitor of the menin-MLL1 interaction. MI-3454 profoundly inhibited proliferation and induced differentiation in acute leukemia cells and primary ...
26 CitationsSource
#1Yuqing Zhang (UTSW: University of Texas Southwestern Medical Center)H-Index: 3
#2Amanda Kirane (UC Davis: University of California, Davis)H-Index: 8
Last. Rolf A. BrekkenH-Index: 75
view all 7 authors...
Resistance to standard therapy remains a major challenge in the treatment of pancreatic ductal adenocarcinoma (PDA). Although anti-VEGF therapy delays PDA progression, therapy-induced hypoxia results in a less differentiated mesenchymal-like tumor cell phenotype, which reinforces the need for effective companion therapies. COX-2 inhibition has been shown to promote tumor cell differentiation and improve standard therapy response in PDA. Here, we evaluate the efficacy of COX-2 inhibition and VEGF...
5 CitationsSource
#1William T. Johnson (Thomas Jefferson University)H-Index: 3
#2Rebecca Kohnken (OSU: Ohio State University)H-Index: 8
Last. Anjali Mishra (OSU: Ohio State University)H-Index: 17
view all 9 authors...
#1Rebecca KohnkenH-Index: 8
#2Betina McNeilH-Index: 6
Last. Anjali MishraH-Index: 17
view all 7 authors...